| 安伟乔 郜旭 吴秀萍 李艳敏 马丽芳.调脂治疗对老年高血压病动脉硬化事件的影响[J].现代生物医学进展英文版,2014,14(29):5708-5711. |
| 调脂治疗对老年高血压病动脉硬化事件的影响 |
| Effects of Rosurastain on Atherosclerotic Events in Elderly with Hypertension |
| |
| DOI： |
| 中文关键词: 老年人 动脉粥样硬化 瑞舒伐他汀 超敏C反应蛋白 白介素-10 |
| 英文关键词: Elderly Atherosclerosis Rosurastain High sensitivity C-reactive protein Interleukin-10(IL-10) |
| 基金项目:黑龙江省教育厅科学技术研究项目（12521299） |
|
| Hits: 743 |
| Download times: 814 |
| 中文摘要: |
| 目的：观察瑞舒伐他汀调脂治疗12 周对80 岁以上老年高血压病患者的疗效、安全性以及对患者心脑血管终点事件的影响
及意义。方法：对44 例80 岁以上老年高血压患者根据血脂情况分为两组，均加用调脂药物（瑞舒伐他汀10 mg/d），观察用药的12
周前后，患者的血压情况，心脑血管事件的发生情况，并记录患者的血脂、超敏C反应蛋白(hs-CRP)、白介素-10（IL-10）、肝功能等
生化指标，进行比较。结果：两组治疗12 周后总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、超敏C 反应蛋白
(hs-CRP)均明显降低(P<0.01)，且在血脂较高组降低的更明显(P<0.01)，高密度脂蛋白胆固醇（HDL-C）、白介素-10（IL-10）均升高
(P<0.01)，血压、脉压心脑血管终点事件在两组患者中均有下降(P<0.05)，肝功能丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶
(AST)无明显变化(P>0.05)。结论：对于80 岁以上的老年高血压患者无论基础血脂水平如何，都有应用调脂药的必要。 |
| 英文摘要: |
| Objective:To explore the effects and safety of rosuvastain in patients over 80 years old with hypertension and to
observe the incidence of cardio-cerebral vascular events in 12 weeks.Methods:44 patients who were over 80 years old with hypertension
were divided into two groups on the base of blood lipid level. They were all treated with rosuvastatain (10 mg/d) for 12 weeks. Blood
pressure level, the incidence of cardio-cerebral vascular events, blood lipid, high sensitivity C-reactive protein (hs-CRP), interleukin 10
(IL-10), and liver function were recorded and compared.Results:All patients with medicines on average 12 weeks, the levels of LDL-C,
TC, TG and hs-CRP decreased after rosuvastatin treatment (P<0.01). The levels of LDL-C, TC, TG and hs-CRP, the incidence of
cardiocerebral vascular events were higher than before (P<0.01). The Ievels of HDL-C and IL-10 were higher (P<0.01). Blood pressure,
pulse pressure and the incidence of cardio-cerebral vascular events decreased (P<0.05). All patients with medicines on average 12 weeks,
aspartate aminotransferase andalanine aminotransferase with no statistically significant difference (P>0.05).Conclusion:Patients who
were over 80 years old with hypertension, no matter which level of blood lipid, should be treated with rosuvastatain. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
